These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35543641)

  • 21. Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.
    Dunn B; Stein P; Cavazzoni P
    JAMA Intern Med; 2021 Oct; 181(10):1276-1278. PubMed ID: 34254984
    [No Abstract]   [Full Text] [Related]  

  • 22. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
    Silvestro S; Valeri A; Mazzon E
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.
    Barakos J; Purcell D; Suhy J; Chalkias S; Burkett P; Marsica Grassi C; Castrillo-Viguera C; Rubino I; Vijverberg E
    J Prev Alzheimers Dis; 2022; 9(2):211-220. PubMed ID: 35542992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.
    Kastanenka KV; Bussiere T; Shakerdge N; Qian F; Weinreb PH; Rhodes K; Bacskai BJ
    J Neurosci; 2016 Dec; 36(50):12549-12558. PubMed ID: 27810931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease.
    Leinenga G; Koh WK; Götz J
    Alzheimers Res Ther; 2021 Apr; 13(1):76. PubMed ID: 33836798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.
    Lin L; Hua F; Salinas C; Young C; Bussiere T; Apgar JF; Burke JM; Kandadi Muralidharan K; Rajagovindan R; Nestorov I
    CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):362-372. PubMed ID: 35029320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
    Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
    Patel KR
    Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
    [No Abstract]   [Full Text] [Related]  

  • 29. Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab.
    Sveikata L; Charidimou A; Viswanathan A
    Stroke; 2022 Jan; 53(1):298-302. PubMed ID: 34905943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revisiting FDA Approval of Aducanumab.
    Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
    N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
    [No Abstract]   [Full Text] [Related]  

  • 31. Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.
    Bastrup J; Hansen KH; Poulsen TBG; Kastaniegaard K; Asuni AA; Christensen S; Belling D; Helboe L; Stensballe A; Volbracht C
    J Alzheimers Dis; 2021; 79(1):249-265. PubMed ID: 33252074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease.
    Gamage KK; Kumar S
    J Neurosci; 2017 Apr; 37(17):4430-4432. PubMed ID: 28446659
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
    Ross EL; Weinberg MS; Arnold SE
    JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
    Vaz M; Silva V; Monteiro C; Silvestre S
    Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
    Liu E; Wang D; Sperling R; Salloway S; Fox NC; Blennow K; Scheltens P; Schmidt ME; Streffer J; Novak G; Einstein S; Booth K; Ketter N; Brashear HR;
    Neurology; 2018 Mar; 90(10):e877-e886. PubMed ID: 29429971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 37. Aducanumab and adenoviral COVID-19 vaccines: increased cerebral hemorrhage risk?
    MohanaSundaram A; Thukani Sathanantham S; Sveikata L; Lalla RS; Sveikatienė R; Kaushik A; Velayutham R
    Expert Rev Neurother; 2022 Apr; 22(4):283-286. PubMed ID: 35275787
    [No Abstract]   [Full Text] [Related]  

  • 38. Aducanumab and the "post-amyloid" era of Alzheimer research?
    Musiek ES; Bennett DA
    Neuron; 2021 Oct; 109(19):3045-3047. PubMed ID: 34582783
    [No Abstract]   [Full Text] [Related]  

  • 39. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.
    Cummings J; Aisen P; Lemere C; Atri A; Sabbagh M; Salloway S
    Alzheimers Res Ther; 2021 May; 13(1):98. PubMed ID: 33971962
    [No Abstract]   [Full Text] [Related]  

  • 40. Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
    Filippi M; Cecchetti G; Spinelli EG; Vezzulli P; Falini A; Agosta F
    JAMA Neurol; 2022 Mar; 79(3):291-304. PubMed ID: 35099507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.